SUBSCRIBE
SUBSCRIBE
News   Drug Development

MediGene, Inc. Drug Extends Pancreatic Cancer Survival

September 16, 2008 | 
1 min read
LONDON, Sept 16 (Reuters) - Patients with inoperable pancreatic cancer live substantially longer when given MediGene's experimental drug EndoTAG-1 on top of standard chemotherapy, according to clinical trial results.
Clinical research Phase 2 Europe
MORE ON THIS TOPIC
Businessman makes employee cuts as part of layoff
Layoffs
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail
March 19, 2026
 · 
1 min read
 · 
Tristan Manalac
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Prohibition sign. Halftone hands cross their fingers in a no entry sign. Refusal, stop gesture. Rejection sign. Warning concept. Newspaper collage
FDA
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting
March 17, 2026
 · 
2 min read
 · 
Heather McKenzie
Cambridge, USA - 8 July 2025. Pfizer office entrance with logo on a modern glass building, surrounded by greenery.
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
March 17, 2026
 · 
1 min read
 · 
Annalee Armstrong